what forecasts do we have for the share price?, page-12

Biota's finances were not that exceptional prior to Biota hitting its all time high of $9.10 on February 24th 1999.$6M loss $4M in the bank, obviously a lot fewer shares at 74M but you talking a spike to $9.10 surely PRR holders aren't expecting that but who knows in this market.
Goodluck with your research.








Preliminary Final Report
Document date: Wed 26 Aug 1998
Published: Wed 26 Aug 1998 00:00:00
Document No: 140316
Document part: C
Market Flag: Y
Classification:

HOMEX - Melbourne

+++++++++++++++++++++++++
(Not Equity Accounted)

CONSOLIDATED PROFIT AND LOSS ACCOUNT
(These figures are NOT equity accounted)
CURRENT PREVIOUS
PERIOD CORRESPONDING
PERIOD
AUD000 AUD000

1.1 Sales (or equivalent operating) revenue 24 59

1.2 Other revenue 1,746 1,464

1.3 Total revenue 1,770 1,523

1.4 Operating profit (loss) before
abnormal items and tax (5,697) (4,101)

1.5 Abnormal items before tax
(detail in item 2.4) (763) -

1.6 Operating profit (loss) before tax
(items 1.4 + 1.5) (6,460) (4,101)

1.7 Less tax - -

1.8 Operating profit (loss) after tax
but before outside equity interests (6,460) (4,101)

1.9 Less outside equity interests - -

1.10 Operating profit (loss) after tax
attributable to members (6,460) (4,101)

1.11 Extraordinary items after tax
(detail in item 2.6) - -

1.12 Less outside equity interests - -

1.13 Extraordinary items after tax
attributable to members - -

1.14 Total operating profit (loss) and
extraordinary items after tax
(items 1.8 + 1.11) (6,460) (4,101)

1.15 Operating profit (loss) and
extraordinary items after tax
attributable to outside equity
interests (items 1.9 + 1.12) - -

1.16 Operating profit (loss) and
extraordinary items after tax
attributable to members
(items 1.10 + 1.13) (6,460) (4,101)

1.17 Retained profits (accumulated losses)
at beginning of financial period (44,406) (40,305)





Announcements released as BTA
Date Price
sens. Headline Pages PDF Edited
text*
11/12/1998 The Lancet Publishes The First Ever Phase 111 Clinical Trial - - Text
03/12/1998 US FDA Clearance to Market Rapid Test for Influenza - - Text
16/11/1998 Presentation of Data - Relenza - - Text
29/10/1998 Results of AGM - - Text
28/10/1998 Chairman`s AGM Address to Shareholders - - Text
28/10/1998 New Drug Application for Relenza with US Food&Drug Admin. - - Text
14/10/1998 Change in substantial shareholding - - Text
14/10/1998 Change in Substantial Shareholding from Norflo Pty Ltd - - Text
29/09/1998 Annual Report/Top 20/Notice of AGM - - Text
28/09/1998 ASIC Annual Audited A/cs - - Text
24/09/1998 Relenza Filing Europe and Canada - - Text
04/09/1998 Diagnostic Distribution Agreement - - Text
26/08/1998 Preliminary Final Report - - Text
24/08/1998 Trial results to be presented at ICAAC Conference - - Text
24/07/1998 Notice re Diabetes Project - - Text
24/06/1998 Year 2000 advice - - Text
04/06/1998 Awarded Start Grant for Common Cold Project - - Text
28/05/1998 Marketing agreement/Glaxo purchases diagnostic tests - - Text
11/05/1998 Advice re Flu Diagnostic - - Text
30/03/1998 Major Milestone for Influenza Drug - - Text
27/03/1998 Information to Shareholders - Biota Update March 1998 - - Text
19/03/1998 ASC Half Yearly Accounts - - Text
25/02/1998 Half Yearly Report - - Text
10/02/1998 Biota&Howard Florey Institute to work on Alzheimer`s Project - - Text
19/01/1998 Anti-Cancer Drug Program Enters New Stage - - Text
13/01/1998 Begin N.American Clinical Trials of Influenza Diagnostic - - Text


http://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=text&issuerId=228&announcementId=352910